• 1
    Harrer G, Hubner W, Prodzuwent I. Effectiveness and tolerance of the hypericum extract LI 160 compared to maprotiline: a multicenter double-blind study. J Geriatr Psychiatry Neurol 1999; 7 (Suppl.): 5248.
  • 2
    Schrader E. Equivalence of St. John’s wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression. Int Clin Psychopharmacol 2000; 15: 618.
  • 3
    Szegedi A, Kohnen R, Dienel A, Kieser M. Acute treatment of moderate to severe depression with hypericum extracts WS 5570 (St John’s wort): randomised controlled double blind non-inferiority trial versus paroxetine. BMJ 2005; 330: 503.
  • 4
    Wheatley D. LI 160, an extract of St. John’s wort, versus amitriptyline in mildly to moderately depressed outpatients—a controlled 6-week clinical trial. Pharmacopsychiatry 1997; 30 (Suppl. 2): 7780.
  • 5
    Woelk H. Comparison of St John’s wort and imipramine for treating depression: randomised controlled trial. BMJ 2001; 321: 5369.
  • 6
    Ruschitzka F, Meier P, Turina M, Luscher T, Noll G. Acute heart transplant rejection due to Saint John’s Wort. Lancet 2000; 355: 5489.
  • 7
    Turtoon-weeks S, Barone G, Gurley B, Ketel B, Lightfoot M, Abul-Ezz S. St John’s wort: a hidden risk for transplant patients. Prog Transplant 2001; 11: 11620.
  • 8
    Henderson L, Yue Q, Bergquist C, Gerden B, Arlett P. St John’s wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol 2002; 54: 34956.
  • 9
    Izzo A, Ernst E. Interactions between herbal medicines and prescription drugs. Drugs 2001; 61: 216375.
  • 10
    Mills E, Montori V, Wu P, Gallicano K, Clarke M, Guyatt G. Interaction of St John’s wort with conventional drugs: systematic review of clinical trials. BMJ 2004; 329: 2730.
  • 11
    Hammerbess P, Basch E, Ulbricht C, Barrette E, Foppa I, Basch S. St John’s wort: a systematic review of adverse effects and drug interactions for the consultation psychiatrist. Psychosomatics 2003; 44: 27182.
  • 12
    Mai I, Bauer S, Perloff E, Johne A, Uchleke B, Frank B, Budde K, Roots I. Hyperforin content determines the magnitude of the St John’s wort–cyclosporin drug interaction. Clin Pharmacol Ther 2004; 76: 33040.
  • 13
    Arold G, Donath F, Maurer A, Diefenbach K, Bauer S, Henneicke-von Zepelin H, Friede M, Roots I. No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John’s wort extract. Planta Med 2005; 71: 3317.
  • 14
    Greeson J, Sanford B, St. Monti D. St John’s wort (Hypericum perforatum) a review of the current pharmacological, toxicological and clinical literature. Psychopharmacology 2001; 153: 40214.
  • 15
    Wurglics M, Westerhoff K, Kaunzinger A, Wilke A, Baumeister A, Dressman J, Schubert-Zsilavecz M. Comparison of German St. John’s Wort products according to hyperforin and total hypericin content. J Am Pharm Assoc 2001; 41: 5606.
  • 16
    Bertz R, Granneman G. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997; 32: 21058.
  • 17
    Watkins P. Noninvasive tests of CYP3A enzymes. Pharmacogen 1994; 4: 17184.
  • 18
    Streetman D, Bertino J, Nafziger A. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogen 2000; 10: 187216.
  • 19
    Bjornsson T, Callaghan D, Einoff H, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach RS, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA. The conduct of in vitro and in vivo drug–drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) Perspective. Drug Metab Dispos 2003; 31: 81532.
  • 20
    Tucker G, Houston J, Huang S. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential—towards a consensus. Pharm Res 2001; 18: 107180.
  • 21
    Gurley B, Gardner S, Hubbard M, Williams K, Gentry B, Cui Y, Ang C. Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly. St John’s wort, garlic oil, Panax ginseng and Ginkgo biloba. Drugs Aging 2005; 22: 52539.
  • 22
    Wang Z, Gorski C, Hammam M, Huang S, Lesko L, Hall S. The effect of St John’s wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 2001; 70: 31726.
  • 23
    Bauer S, Stromer E, Kerb R, Johne A, Brockmoller J, Roots I. Differential effects of Saint John’s Wort (Hypericum perforatum) on the urinary excretion of d-glucaric acid and 6-beta-hydroxycortisol in healthy volunteers. Eur J Clin Pharmacol 2002; 58: 5815.
  • 24
    Bauer S, Stromer E, Johne A, Kruger H, Klemens B, Neumayer H, Roots I, Mai I. Alterations in cyclosporin A pharacokinetics and metabolism during treatment with St John’s wort in renal transplant patients. Br J Clin Pharmacol 2003; 55: 20311.
  • 25
    Dresser G, Schwarz U, Wilkinson G, Kim R. Coordinate induction of both cytochrome P4503A and MDR1 by St John’s wort in healthy subjects. Clin Pharmacol Ther 2003; 73: 4150.
  • 26
    Durr D, Stieger B, Kullak-Ublick G, Rentsch K, Steinert H, Meier P, Fattinger K. St John’s wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 2000; 68: 598604.
  • 27
    Frye R, Fitzgerald S, Lagattuta T, Hruska M, Egorin M. Effect of St John’s wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther 2004; 76: 3239.
  • 28
    Herbert M, Park J, Chen Y, Akhtar S, Larson A. Effects of St. John’s Wort (Hypericum perforatum) on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol 2004; 44: 8994.
  • 29
    Johne A, Schmider J, Brockmoller J, Stradelmann A, Strormer E, Bauer S, Scholler G, Langheinrich M, Roots I. Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John’s wort (Hypericum perforatum). J Clin Psychopharmacol 2002; 22: 4654.
  • 30
    Mai I, Stormer E, Bauer S, Kruger H, Budde K, Roots I. Impact of St John’s wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. Nephrol Dial Transplant 2003; 18: 81922.
  • 31
    Markowitz J, Donovan J, DeVane C, Taylor R, Ruan Y, Wang J, Chavin K. Effect of St John’s wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 2003; 290: 15004.
  • 32
    Pfunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J. Interaction of St John’s wort with a low-dose oral contraceptive therapy: a randomised controlled trial. Br J Clin Pharmacol 2003; 56: 68390.
  • 33
    Wenk M, Todesco L, Krahenbuhl S. Effect of St John’s wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xantine oxidase in healthy males and females. Br J Clin Pharmacol 2004; 57: 4959.
  • 34
    Smith P, Bullock J, Booker B, Hass C, Berensn C, Jusko W. Induction of imatinib metabolism by Hypericum perforatum. Blood 2004; 104: 122930.
  • 35
    Wang L, Zhou G, Zhu B, Wu J, Wang J, El-Aty A, Li T, Liu J, Yang T, Wang D, Zhong X, Zhou H. St John’s wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Clin Pharmacol Ther 2004; 75: 1917.
  • 36
    Gurley B, Gardner S, Hubbard M, Williams K, Gentry B, Cui Y, Ang C. Cytochrome P450 phenotypic ratios for predicting herb–drug interactions in humans. Clin Pharmacol Ther 2002; 72: 27687.
  • 37
    Hall S, Wang Z, Huang S, Hammas M, Vasavada N, Adigun A, Hilligoss J, Miller M, Gorksi C. The interaction between St John’s wort and an oral contraceptive. Clin Pharmacol Ther 2003; 74: 52535.
  • 38
    Jiang X, Williams K, Liauw W, Ammit A, Roufogalis B, Duke C, Day R, McLachlan A. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 2004; 59: 42532.
  • 39
    Tannergren C, Engman H, Knutson L, Hedeland M, Bondesson U, Kennernas H. St John’s wort decreases the bioavailability of R- and S-verapamil through induction of first-pass metabolism. Clin Pharmacol Ther 2004; 75: 298309.
  • 40
    Brattstrom A. St John’s wort extract (Ze 117) does not alter the kinetics of a low dose oral contraceptive (unpublished data) 2005.
  • 41
    Burstein A, Horton R, Dunn T, Alfaro R, Piscitelli S, Theodore W. Lack of effect of St John’s wort on carbamazepine pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 2000; 68: 60512.
  • 42
    Piscitelli S, Burstein A, Chaitt D, Alfaro R, Falloon J. Indinavir concentrations and St John’s wort. Lancet 2000; 355: 5478.
  • 43
    Roby C, Anderson G, Kanton E, Dryer D, Burstein A. St John’s Wort: effect on CYP3A4 activity. Clin Pharmacol Ther 2000; 67: 4517.
  • 44
    Kawaguchi A, Ohmori M, Tsufuoke S, Nishiki K, Harada K, Miyamori I, Yano R, Nakamura T, Masada M, Fujimura A. Drug interaction between St John’s wort and quazepam. Br J Clin Pharmacol 2004; 58: 40310.
  • 45
    Sugimoto K, Ohmori M, Tsuruoka S, Nishiki K, Kawaguchi A, Harada K, Arakawa M, Sakamoto K, Masada M, Miyamori I, Fujimura A. Different effects of St John’s wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther 2001; 70: 51824.
  • 46
    Morimoto T, Kotegawa T, Tsutsumi K, Ohtani Y, Imai H, Nakano S. Effect of St John’s wort on the pharmacokinetics of theophylline in healthy volunteers. J Clin Pharmacol 2004; 44: 95101.
  • 47
    Markowitz J, DeVane C, Boulton D, Carson S, Nahas Z, Risch S. Effect of St John’s wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. Life Sci 2000; 66: 1339.
  • 48
    Mathijssen R, Verweoj J, Bruijn P, Loos W, Sparreboom A. Effects of St John’s wort on irinotecan metabolism. J Natl Cancer Inst 2002; 94: 12479.
  • 49
    Xie R, Tan L, Polasek E, Hong C, Teillol-Foo M, Gordi T, Sharma A, Nickens D, Arakawa T, Knuth D, Antal E. CYP3A and P-glycoprotein activity induction with St. John’s wort. J Clin Pharmacol 2005; 45: 3526.
  • 50
    Mills E, Wu P, Johnston B, Gallicano K, Clarke M, Guyatt G. Natural health product–drug interactions: a systematic review of clinical trials. Ther Drug Monit 2005; 27: 54957.
  • 51
    Food and Drug Administration. In Vivo Drug Metabolism/Drug Interaction Studies–Study Design, Data Analysis, and Recommendations for Dosing and Labelling. Rockville, MD: FDA 1999.
  • 52
    Moore B, Goodwin B, Jones S, Wisey G, Serabjit-Singh C, Wilson T, Collins J, Kliewer S. St John’s wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 2000; 97: 75002.
  • 53
    Wentworth J, Agostini M, Love J, Schwabe J, Chatterjee V. St John’s wort, a herbal antidepressant, activates the steroid X receptor. J Endocrinol 2000; 166: R11R16.
  • 54
    Cantoni L, Rozio M, Mangolini A, Hauri L, Caccia S. Hyperforin contributes to the hepatic CYP3A-inducing effect of Hypericum perforatum extract in the mouse. Toxicol Sci 2003; 75: 2530.
  • 55
    Zanoli P. Role of hyperforin in the pharmacological activities of St. John’s wort. CNS Drug Rev 2004; 10: 20318.
  • 56
    Greeson J, Sanford B, Monti D. St John’s wort (Hypericum perforatum): a review of the current pharmacological, toxicological and clinical literature. Psychopharmacology 2004; 153: 40214.
  • 57
    Meier B. Comparing phytopharmaceuticals: the example of St. John’s wort. Adv Ther 2001; 18: 3546.
  • 58
    Kaufeler R, Meier B, Brattstrom A. Efficacy and tolerability of Ze 117 St. John’s wort extract in comparison with placebo, imipramine and fluoxetrine for the treatment of mild to moderate depression according to ICD-10. An overview. Pharmacopsychiatry 2001; 34 (Suppl. 1): S49S50.
  • 59
    Johne A, Brockmoller J, Bauer S, Maurer A, Langheinrich M, Roots I. Pharmacokinetic interactions of digoxin with an herbal extract from St John’s wort (Hypericum perforatum). Clin Pharmacol Ther 1999; 66: 33845.
  • 60
    Wang Z, Hammam M, Huang S, Lesko L, Hall S. Effect of St John’s wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther 2002; 71: 41420.
  • 61
    Takanaga H, Ohnishi A, Murakami H, Matsuo H, Higuchi S, Urae A, Irie S, Furuie H, Matsukuma K, Kimura M, Kawano K, Orii Y, Tanaka T, Sawada Y. Relationship between time after intake of grapefruit juice and the effect on pharmacokinetics and pharmacodynamics of nisoldipine in healthy subjects. Pharmacokin Drug Dispos 2000; 67: 20114.